Long‐term follow‐up of intradetrusor botulinum toxin utilisation: A comparison of patients with multiple sclerosis and idiopathic overactive bladder
Abstract Objectives To assess long‐term outcomes (up to 10 cycles) of repeated intradetrusor botulinum toxin (BoNT) utilisation in multiple sclerosis (MS) and idiopathic overactive bladder (OAB). Materials and Methods This is a retrospective, international, multi‐centre, observational cohort study o...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | BJUI Compass |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/bco2.479 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576688352919552 |
|---|---|
| author | William Chui Joshua Kealey Henry H. Yao Garson Chan Alvaro Bazo Richard Parkinson Helen E. O'Connell Johan Gani |
| author_facet | William Chui Joshua Kealey Henry H. Yao Garson Chan Alvaro Bazo Richard Parkinson Helen E. O'Connell Johan Gani |
| author_sort | William Chui |
| collection | DOAJ |
| description | Abstract Objectives To assess long‐term outcomes (up to 10 cycles) of repeated intradetrusor botulinum toxin (BoNT) utilisation in multiple sclerosis (MS) and idiopathic overactive bladder (OAB). Materials and Methods This is a retrospective, international, multi‐centre, observational cohort study of patients diagnosed with MS and neurogenic OAB and treated with intradetrusor BoNT between January 2005 and January 2020 (just prior to COVID‐19 interruption). Dose, efficacy, duration of effect, International Consultation on Incontinence Questionnaire Overactive Bladder (ICIQ‐OAB) and International Consultation on Incontinence Questionnaire Urinary Incontinence (ICIQ‐UI) measures and complication rates were recorded. Comparisons were made to those with idiopathic OAB. Results Seven hundred and ninety‐two patients received intradetrusor BoNT treatment (104 had MS with neurogenic OAB and 688 had idiopathic OAB). Patients with MS were more likely to receive higher doses of BoNT in all cycles. Self‐reported efficacy ranged from 85.7 to 100% (MS) and 87.2 to 100% (idiopathic) with MS patients reporting increased efficacy in cycles 1–3 comparatively (p < 0.05). Duration of effect ranged from 4.5 to 9 months with a reduction in the MS cohort between cycles 1 and 10 (median 8 months vs. 5 months, p = 0.0156). Conclusion Patients with MS and neurogenic OAB have a good therapeutic effect from intradetrusor BoNT that is sustained over at least 10 cycles with significant reduction in the duration of action with subsequent cycles. |
| format | Article |
| id | doaj-art-5fcfcde92e60449fa80013fca83527a5 |
| institution | Kabale University |
| issn | 2688-4526 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | BJUI Compass |
| spelling | doaj-art-5fcfcde92e60449fa80013fca83527a52025-01-31T00:14:32ZengWileyBJUI Compass2688-45262025-01-0161n/an/a10.1002/bco2.479Long‐term follow‐up of intradetrusor botulinum toxin utilisation: A comparison of patients with multiple sclerosis and idiopathic overactive bladderWilliam Chui0Joshua Kealey1Henry H. Yao2Garson Chan3Alvaro Bazo4Richard Parkinson5Helen E. O'Connell6Johan Gani7Department of Urology, Western Health University of Melbourne Melbourne AustraliaDepartment of Urology, Eastern Health Melbourne AustraliaDepartment of Urology, Western Health University of Melbourne Melbourne AustraliaDepartment of Urology, Western Health University of Melbourne Melbourne AustraliaDepartment of Urology Nottingham University Hospitals NHS Trust Nottingham UKDepartment of Urology Nottingham University Hospitals NHS Trust Nottingham UKDepartment of Urology, Western Health University of Melbourne Melbourne AustraliaDepartment of Urology, Western Health University of Melbourne Melbourne AustraliaAbstract Objectives To assess long‐term outcomes (up to 10 cycles) of repeated intradetrusor botulinum toxin (BoNT) utilisation in multiple sclerosis (MS) and idiopathic overactive bladder (OAB). Materials and Methods This is a retrospective, international, multi‐centre, observational cohort study of patients diagnosed with MS and neurogenic OAB and treated with intradetrusor BoNT between January 2005 and January 2020 (just prior to COVID‐19 interruption). Dose, efficacy, duration of effect, International Consultation on Incontinence Questionnaire Overactive Bladder (ICIQ‐OAB) and International Consultation on Incontinence Questionnaire Urinary Incontinence (ICIQ‐UI) measures and complication rates were recorded. Comparisons were made to those with idiopathic OAB. Results Seven hundred and ninety‐two patients received intradetrusor BoNT treatment (104 had MS with neurogenic OAB and 688 had idiopathic OAB). Patients with MS were more likely to receive higher doses of BoNT in all cycles. Self‐reported efficacy ranged from 85.7 to 100% (MS) and 87.2 to 100% (idiopathic) with MS patients reporting increased efficacy in cycles 1–3 comparatively (p < 0.05). Duration of effect ranged from 4.5 to 9 months with a reduction in the MS cohort between cycles 1 and 10 (median 8 months vs. 5 months, p = 0.0156). Conclusion Patients with MS and neurogenic OAB have a good therapeutic effect from intradetrusor BoNT that is sustained over at least 10 cycles with significant reduction in the duration of action with subsequent cycles.https://doi.org/10.1002/bco2.479bladderdetrusorefficacyincontinencemultiple sclerosisneurogenic |
| spellingShingle | William Chui Joshua Kealey Henry H. Yao Garson Chan Alvaro Bazo Richard Parkinson Helen E. O'Connell Johan Gani Long‐term follow‐up of intradetrusor botulinum toxin utilisation: A comparison of patients with multiple sclerosis and idiopathic overactive bladder BJUI Compass bladder detrusor efficacy incontinence multiple sclerosis neurogenic |
| title | Long‐term follow‐up of intradetrusor botulinum toxin utilisation: A comparison of patients with multiple sclerosis and idiopathic overactive bladder |
| title_full | Long‐term follow‐up of intradetrusor botulinum toxin utilisation: A comparison of patients with multiple sclerosis and idiopathic overactive bladder |
| title_fullStr | Long‐term follow‐up of intradetrusor botulinum toxin utilisation: A comparison of patients with multiple sclerosis and idiopathic overactive bladder |
| title_full_unstemmed | Long‐term follow‐up of intradetrusor botulinum toxin utilisation: A comparison of patients with multiple sclerosis and idiopathic overactive bladder |
| title_short | Long‐term follow‐up of intradetrusor botulinum toxin utilisation: A comparison of patients with multiple sclerosis and idiopathic overactive bladder |
| title_sort | long term follow up of intradetrusor botulinum toxin utilisation a comparison of patients with multiple sclerosis and idiopathic overactive bladder |
| topic | bladder detrusor efficacy incontinence multiple sclerosis neurogenic |
| url | https://doi.org/10.1002/bco2.479 |
| work_keys_str_mv | AT williamchui longtermfollowupofintradetrusorbotulinumtoxinutilisationacomparisonofpatientswithmultiplesclerosisandidiopathicoveractivebladder AT joshuakealey longtermfollowupofintradetrusorbotulinumtoxinutilisationacomparisonofpatientswithmultiplesclerosisandidiopathicoveractivebladder AT henryhyao longtermfollowupofintradetrusorbotulinumtoxinutilisationacomparisonofpatientswithmultiplesclerosisandidiopathicoveractivebladder AT garsonchan longtermfollowupofintradetrusorbotulinumtoxinutilisationacomparisonofpatientswithmultiplesclerosisandidiopathicoveractivebladder AT alvarobazo longtermfollowupofintradetrusorbotulinumtoxinutilisationacomparisonofpatientswithmultiplesclerosisandidiopathicoveractivebladder AT richardparkinson longtermfollowupofintradetrusorbotulinumtoxinutilisationacomparisonofpatientswithmultiplesclerosisandidiopathicoveractivebladder AT heleneoconnell longtermfollowupofintradetrusorbotulinumtoxinutilisationacomparisonofpatientswithmultiplesclerosisandidiopathicoveractivebladder AT johangani longtermfollowupofintradetrusorbotulinumtoxinutilisationacomparisonofpatientswithmultiplesclerosisandidiopathicoveractivebladder |